RESUMEN
OBJECTIVE: To study the correlation between isoeitratedehydrogenasel 1 (IDH1) mutation and prognosis in supratentorial high-grade astrocytomas. METHODS: There were 217 samples of supratentorial high-grade astrocytomas specimens collected for DNA extraction, IDH1 mutation of each patient was determined by PCR and direct sequencing. The differences of clinical features were compared between mutant group and wild type group. The relationship between IDH1 mutation and overall survival of the patients was studied with Kaplan-Meier survival curve, while multiple factors analysis was carried out by COX regression model. RESULTS: There were 43 (19.3%) IDH1 mutations in 217 specimens, of which 9 (24.3%) in WHO grade III, 34 (18.9%) in WHO grade IV. The mean age of primary glioblastoma multiforme (GBM) in mutant type group and wild type group were 39.17 and 47.66 years old respectively (P < 0.05). The median survival time was 64 weeks for the patients in IDH1 mutation group and 50 weeks for those in wild type group, and the difference was statistically significant (P < 0.001). The median survival time was 51 weeks for the wild type group of WHO grade III cases and 58 weeks for the mutant group of WHO grade IV cases (P < 0.001). COX multiple variable analysis showed that IDH1 mutation, surgical resection, preoperative Karnofsky performance, radiotherapy and chemotherapy were statistically significant in prognosis (P < 0.05). CONCLUSION: IDH1 mutation can be found in supratentorial high-grade astrocytomas, the patients with IDH1 mutation may have a better prognosis.
Asunto(s)
Astrocitoma/genética , Glioblastoma/genética , Isocitrato Deshidrogenasa/genética , Mutación , Neoplasias Supratentoriales/genética , Adolescente , Adulto , Anciano , Anciano de 80 o más Años , Astrocitoma/patología , Secuencia de Bases , Femenino , Glioblastoma/patología , Humanos , Masculino , Persona de Mediana Edad , Datos de Secuencia Molecular , Clasificación del Tumor , Pronóstico , Modelos de Riesgos Proporcionales , Neoplasias Supratentoriales/patología , Tasa de Supervivencia , Adulto JovenRESUMEN
OBJECTIVE: To investigate the relationship between isocitrate dehydrogenase 1 (IDH1) mutation and clinicopathological features in human supratentorial WHO grade II gliomas. METHODS: Ninety five supratentorial WHO grade II glioma patients were treated in our department from January 2009 to January 2011. The clinical data and tumor samples of each patient were collected. IDH1 mutation in the tumor was measured by sequencing the IDH1 gene of tumor specimen. The relationship between IDH1 mutation and the clinicopathological features was analyzed. RESULTS: There were 69 cases (72.6%) with IDH1 mutations were found, all of which were R132H type mutations. The mutation rates of diffuse astrocytoma, oligodendroglioma and oligoastrocytoma were 73.6%, 68.8% and 73.1% respectively. The mean ages of IDH1 mutant group and wild type group were significantly different [(39 6 +/- 7.4) yr. vs. (46.9 +/- 11.6) yr., P < 0.05). The mutant rates of patients aged > or = 50 years and < 50 years were 43.8% and 78.5% respectively (P < 0.05), while those of male patients and female patients were 68.6% and 77.3% respectively (P > 0.05). The mutant rates of patients whose tumor > or = 5 cm and < 5 cm were 60.0% and 90.0% respectively (P < 0.05), while those of monolobe involvement group and deepen structures involvement group were 93.3% and 32.0% respectively (P < 0.05). CONCLUSION: The mutation of IDH1 in supratentorial WHO grade II glioma is common, and is associated with patients' age, tumor size and tumor location.